Acorda Therapeutics to Acquire Civitas Therapeutics * Obtains global rights for Phase 3 Parkinson's disease treatment * Acquisition leverages existing Acorda development and commercial capabilities * Company to host webcast at 8:30 a.m. Eastern ARDSLEY, N.Y.-- --Acorda Therapeutics, Inc. today announced that it entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson's disease .
http://ift.tt/1xeEg5v
http://ift.tt/1xeEg5v
No comments:
Post a Comment